Therapeutics News and Research

RSS

Acorda Therapeutics initiates second clinical trial of Glial Growth Factor 2 in heart failure patients

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the first patient has been enrolled in the second clinical trial of Glial Growth Factor 2 (GGF2). This Phase 1b single-infusion trial in people with heart failure will assess tolerability of three dose levels of GGF2, and also includes several explorative measures of efficacy.

9 Oct 2013

Forma Achieves First Milestone In Celgene Collaboration

...

8 Oct 2013

Horizon Medicare beneficiaries to receive pharmacy services through Prime Therapeutics

Beginning January 1, 2014, Horizon Healthcare Services, Inc. Medicare beneficiaries will receive pharmacy services through Prime Therapeutics LLC. Prime began providing pharmacy benefit management services to the plan's commercial members July 1, 2013.

8 Oct 2013

Brain & Behavior Research Foundation to hold research symposium on mental health

The Brain & Behavior Research Foundation, an organization dedicated to improving the lives of those with mental illness through the transformative power of neuroscience and psychiatric research, will hold its 25th Annual Mental Health Research Symposium on Friday, October 25th from 9:00 am to 4:30 p.m. at the Kaufman Music Center, located at 129 W. 67th St. in New York City.

8 Oct 2013

Two researchers receive $2.5M grant to continue their research on cancer cell growth

A pair of researchers at Rutgers Cancer Institute of New Jersey has been awarded nearly $2.5 million dollars to further study in their respective laboratories.

8 Oct 2013

GSK Adds Another Program To Isis Antisense Collab

...

7 Oct 2013

Experimental Therapeutics, Debiopharm join to develop oral small molecules targeting new class of epigenetic modulators

The Agency for Science, Technology and Research (A*STAR)'s Experimental Therapeutics Centre (ETC), a center of excellence to advance and accelerate drug discovery in Singapore, and Debiopharm Group™ (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology as well as companion diagnostics, today announced the signature of an exclusive research collaboration to develop oral small molecules targeting new class of epigenetic modulators.

7 Oct 2013

Kiadis Pharma signs Services Agreement with GRCBDS for Phase II clinical study with ATIR

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that a Services Agreement has been signed with the German Red Cross Blood Donor Service Baden-Wuerttemberg-Hessen (GRCBDS) whereby GRCBDS will provide pharmaceutical development and GMP manufacturing services for Kiadis Pharma's ongoing Phase II clinical study with ATIR™.

7 Oct 2013

Scientists at Oklahoma Medical Research Foundation identify six new Sj-gren-related genes

With the completion of the first genome-wide association study for Sj-gren's syndrome, an international coalition of researchers led by scientists at the Oklahoma Medical Research Foundation has identified six new disease-related genes.

7 Oct 2013

Anti-inflammatory mechanism leads to development of oral medications for atherosclerosis, IBS

Research led by Charles Nichols, PhD, Associate Professor of Pharmacology at LSU Health Sciences Center New Orleans, describes a powerful new anti-inflammatory mechanism that could lead to the development of new oral medications for atherosclerosis and inflammatory bowel disorders (IBS).

7 Oct 2013

ERK pathway discovery may provide therapeutic options for treating drug addictions

The extracellular-signal regulated kinase (ERK) pathway plays a role in multiple drug addictions and appears to modulate neuronal plasticity through epigenetic mechanisms, say French scientists.

7 Oct 2013

MIT investigators receive DARPA grant to develop new technologies for BioMOD program

Investigators from MIT's Biomanufacturing Research Program (BioMAN) have received a $10.4 million grant from the Defense Advanced Research Projects Agency (DARPA) to develop new technologies for DARPA's Biologically-derived Medicines On Demand (BioMOD) program.

5 Oct 2013

Prime Therapeutics Honored With Silver Award For Best Practices In Care Coordination And Clinical Integration By URAC

Prime Therapeutics' (Prime) efforts to improve patient health and reduce health care costs were recognized on Oct. 1 at the URAC Quality Summit in Washington, D.C.

5 Oct 2013

Researchers discover way to use stem cells as drug delivery vehicles

A group of Brigham and Women's Hospital, and Harvard Stem Cell Institute researchers and collaborators at MIT and MGH have found a way to use stem cells as drug delivery vehicles.

5 Oct 2013

New technique for breast cancer treatment and prevention-injection via nipple

JoVE, the Journal of Visualized Experiments, will publish a new technique for breast cancer treatment and prevention-injection of therapeutics via the nipple.

5 Oct 2013

Autism Speaks launches the Preclinical Autism Consortium for Therapeutics

Autism Speaks, the world's leading autism science and advocacy organization, today announced the launch of the Preclinical Autism Consortium for Therapeutics (PACT).

4 Oct 2013

Cholesterol-lowering drugs could be alternative treatment for people who take statins

A new class of cholesterol-lowering drugs that target a recently discovered regulator of harmful cholesterol could be an alternative or complementary treatment for the 30 million people who take statins, after the first trial in humans confirms the technique’s feasibility and safety.

4 Oct 2013

Data from Flexion Therapeutics' FX006 Phase 2b trial for OA to be presented at ACR/ARHP meeing

Flexion Therapeutics, Inc. announced today that new data from a Phase 2b dose-ranging trial of the company's lead compound, FX006, in osteoarthritis has been accepted for an oral presentation at the 2013 Annual Scientific Meeting of the American College of Rheumatology and the Association of Rheumatology Health Professionals.

2 Oct 2013

Final patient completion of phase II study of TR040303 in patients treated for acute myocardial infarction announced by Trophos

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announces today the final patient completion of a phase II study of TR040303 in patients treated for acute myocardial infarction (MI). Outcome data of this study is expected to be available towards the end of 2013.

2 Oct 2013

Validation of thrombin generation assay (TGA) for an IVIG drug announced by Haemtech Biopharma Services

Haemtech Biopharma Services (HBS) is pleased to announce the successful validation of a thrombin generation assay (TGA) for an IVIG drug. The assay was validated in 2012 to support the use of TGA as a release assay for Biotest Pharmaceuticals Corporation's U.S. Food and Drug Administration Biologics License Application for BIVIGAM® [Immune Globulin Intravenous (Human), 10% Liquid] product. The validated TGA assay was designed and performed on the Calibrated Automated Thrombogram® platform (CAT) from Diagnostica Stago, Inc. (Parsippany, NJ).

1 Oct 2013

Therapeutics News and Research

Acorda Therapeutics initiates second clinical trial of Glial Growth Factor 2 in heart failure patients

Forma Achieves First Milestone In Celgene Collaboration

Horizon Medicare beneficiaries to receive pharmacy services through Prime Therapeutics

Brain & Behavior Research Foundation to hold research symposium on mental health

Two researchers receive $2.5M grant to continue their research on cancer cell growth

GSK Adds Another Program To Isis Antisense Collab

Experimental Therapeutics, Debiopharm join to develop oral small molecules targeting new class of epigenetic modulators

Kiadis Pharma signs Services Agreement with GRCBDS for Phase II clinical study with ATIR

Scientists at Oklahoma Medical Research Foundation identify six new Sj-gren-related genes

Anti-inflammatory mechanism leads to development of oral medications for atherosclerosis, IBS

ERK pathway discovery may provide therapeutic options for treating drug addictions

MIT investigators receive DARPA grant to develop new technologies for BioMOD program

Prime Therapeutics Honored With Silver Award For Best Practices In Care Coordination And Clinical Integration By URAC

Researchers discover way to use stem cells as drug delivery vehicles

New technique for breast cancer treatment and prevention-injection via nipple

Autism Speaks launches the Preclinical Autism Consortium for Therapeutics

Cholesterol-lowering drugs could be alternative treatment for people who take statins

Data from Flexion Therapeutics' FX006 Phase 2b trial for OA to be presented at ACR/ARHP meeing

Final patient completion of phase II study of TR040303 in patients treated for acute myocardial infarction announced by Trophos

Validation of thrombin generation assay (TGA) for an IVIG drug announced by Haemtech Biopharma Services

Event guide: The Non-Opioid Pain Therapeutics Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News